AEZ. AEterna Zentaris Inc.

Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

Aeterna Zentaris to Announce Second Quarter 2018 Financial and Operating Results on August 9, 2018

CHARLESTON, S.C., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) will announce its second quarter 2018 financial and operating results after market close on Thursday, August 9, 2018. The Company will host a conference call to discuss these results on Friday, August 10, 2018 at 8:30 a.m. Eastern Time.

Participants may access the conference call by telephone using the following numbers:

  • Toll-Free: 877-407-8029, Confirmation #13681858
  • Toll: 201-689-8029, Confirmation #13681858

A replay will also be available on the Company’s website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency.  Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit .

Contact:

Aeterna Zentaris Inc.

James Clavijo

Chief Financial Officer



843-900-3201

EN
02/08/2018

Underlying

AEZ.AEterna Zentaris Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AEterna Zentaris Inc.

 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director

COSCIENS Biopharma Announces Appointment of Pierre Labbé as Director TORONTO, ONTARIO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, announced the appointment of Pierre Labbé to its board of directors and as Chair of the Company’s Audit Committee, effective today, to fill the vacancy created by the resignation of Dennis Turpin, also effective today. Mr. Labbé has more...

October 1, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Manage...

COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today provided an update on the progress of its merger integration with Ceapro Inc. (“Ceapro”), including planned changes to its management team and advancements across its current ...

September 23, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-T...

COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety of macimorelin confirmed in the pediatric population TORONTO, ONTARIO, Aug. 27, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company developing and commerci...

August 27, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results                 Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone deficiency expected in Q3 2024 Company ended the quarter with US$27.8 million in cash         TORONTO, ONTARIO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) (“COSCIENS” or the “Company”), a specialty biopharmaceutical company which develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical and pharmaceutical products, today report...

August 13, 2024 1 EN
 PRESS RELEASE
Free
AEZ. AEterna Zentari...

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc.

Aeterna Zentaris Inc. Announces Name Change to COSCIENS Biopharma Inc. TORONTO, ONTARIO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (formerly Aeterna Zentaris Inc.) (NASDAQ: AEZS) (TSX: AEZS) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for healthcare and cosmetics industries, today announces that the Company’s name has been changed from “Aeterna Zentaris Inc.” to “COSCIENS Biopharma Inc.”, effective as of August 6, 2024 (the “Name ...

August 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch